主持国家自然科学基金3项和省自然科学基金（2016年面上项目）1项。

2. 主持制药企业创新药物研究合作项目6项

Chen Y, Zhao K, Liu F, Li Y, Zhong Z, Hong S, Liu X*, Liu L*. Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of In Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model. Drug Metab Dispos. 2018 Jun; 46(6): 897-907.

2. Xu J, Zhang M, Zhang X, Yang H, Sun B, Wang Z, Zhou Y, Wang S, Liu X*, Liu L*. Contribution of Hepatic Retinaldehyde Dehydrogenase Induction to Impairment of Glucose Metabolism by High-Fat-Diet Feeding in C57BL/6J Mice. Basic Clin Pharmacol Toxicol. 2018 May 12. doi: 10.1111/bcpt.13039.

3. Sun B, Zhong Z, Wang F, Xu J, Xu F, Kong W, Ling Z, Shu N, Li Y, Wu T, Zhang M, Zhu L, Liu X*, Liu L*. Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol-dependent glucose transporter 4 translocation. Biochem Pharmacol. 2018; 150:108-119.

4. Liu L, Miao M, Chen Y, Wang Z, Sun B, Liu X*. Altered function and expression of ABC transporters at the blood–brain barrier and increased brain distribution of phenobarbital in acute liver failure mice. Front Pharmacol. 2018; 9:190. doi: 10.3389/fphar.2018.00190

5. Wang F, Miao MX, Sun BB, Wang ZJ, Tang XG, Chen Y, Zhao KJ, Liu XD*, Liu L*. Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp. Acta Pharmacol Sin. 2017 Aug 3. doi: 10.1038/aps.2017.54.

6. Chen Y, Zhao K, Liu F, Xie Q, Zhong Z, Miao M, Liu X*, Liu L*. Prediction of Deoxypodophyllotoxin Disposition in Mouse, Rat, Monkey, and Dog by Physiologically Based Pharmacokinetic Model and the Extrapolation to Human. Front Pharmacol. 2016 Dec 16; 7:488. doi: 10.3389/fphar.2016.00488.

7. Shu N, Hu M, Ling Z, Liu P, Wang F, Xu P, Zhong Z, Sun B, Zhang M, Li F, Xie Q, Liu X*, Liu L*. The enhanced atorvastatin hepatotoxicity in diabetic rats was partly attributed to the upregulated hepatic Cyp3a and SLCO1B1. Sci Rep. 2016 Sep 14;6:33072. doi: 10.1038/srep33072.

8. Liu L, Miao M, Zhong Z, Xu P, Chen Y, Liu X*. Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in rats. Acta Pharmacol Sin. 2016; 37(4): 561-70.

9. Ling Z, Shu N, Xu P, Wang F, Zhong Z, Sun B, Li F, Zhang M, Zhao K, Tang X, Wang Z, Zhu L, Liu L*, Liu X*. Involvement of pregnane X receptor in the impaired glucose utilization induced by atorvastatin in hepatocytes. Biochem Pharmacol. 2016; 100: 98-111.

10. Liu C, Hu M, Guo H, Zhang M, Zhang J, Li F, Zhong Z, Chen Y, Li Y, Xu P, Li J, Liu L*, Liu X*. Combined Contribution of Increased Intestinal Permeability and Inhibited Deglycosylation of Ginsenoside Rb1 in Intestinal Tract to the Enhancement of Ginsenoside Rb1 Exposure in Diabetic Rats Following Oral Administration. Drug Metab Dispos. 2015; 43(11): 1702-10.

11. Li J, Guo HF, Liu C, Zhong Z, Liu L*, Liu XD*. Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model. Clin Pharmacokinet. 2015; 54(2):179-93.

12. Liu L, Liu XD*. Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances. Front Pharmacol. 2014; 5: 273.